drugset / Trial / NCT03594890
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
RandomizedSequentialDouble-blindPrevention
Summary
The present study is a first-in-man clinical trial evaluating OVX836, a recombinant broad spectrum vaccine for Influenza. This clinical trial will evaluate the safety and the immune response of increasing doses of OVX836 after intramuscular or intranasal administrations in healthy volunteers.
Timeline
- Start
- 2018-06-12
- Primary completion
- 2019-08-07
- Completion
- 2019-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OVX836 | Vaccine | 30 ug | Intramuscular |
| Subject | OVX836 | Vaccine | 90 ug | Intramuscular |
| Subject | OVX836 | Vaccine | 180 ug | Intramuscular |